Saturna Capital, an investment management firm, published its “Amana Funds” fourth-quarter 2021 investor letter – a copy of which can be downloaded here. For the fourth quarter of 2021, the Amana Income Fund Investor Shares returned 13.76% and the Institutional Shares returned 13.85%. The Amana Growth Fund sprinted to a strong finish in the fourth quarter, wrapping up an outstanding year by any measure. For the three months ended December 31, 2021, the Amana Growth Fund Investor Shares returned 14.41%, significantly outpacing the 6.91% Morningstar “Large Growth” category return, as well as the 11.03% return of the S&P 500. For the 2021 calendar year, Amana Developing World Fund Investor Shares returned 7.31% versus -2.54% for the MSCI Emerging Markets Index. Spare some time to check the fund’s top 5 holdings to have a clue about their top bets for 2022.
Saturna Capital Amana Funds, in its Q4 2021 investor letter, mentioned Bristol-Myers Squibb Company (NYSE:BMY) and discussed its stance on the firm. Founded in 1887, Bristol-Myers Squibb Company is a Clinton, New York-based pharmaceutical company with a $148.5 billion market capitalization, and is currently spearheaded by its CEO, Giovanni Caforio. BMY delivered a 9.27% return since the beginning of the year, while its 12-month returns are up by 11.82%. The stock closed at $68.13 per share on March 09, 2022.
Here is what Saturna Capital Amana Funds has to say about Bristol-Myers Squibb Company (NYSE:BMY) in its Q4 2021 investor letter:
“Given the likelihood of rising inflation and interest rates ahead, we anticipate adjustments to the portfolio to reduce exposure to highly valued stocks dependent on low interest rates to support terminal year valuations, while seeking investments in companies more correlated with a return to economic normalcy. We sold our positions in Bristol Myers. We believe there are better opportunities than Bristol in pharmaceuticals.”
Copyright: katrintimoff / 123RF Stock Photo
Our calculations show that Bristol-Myers Squibb Company (NYSE:BMY) was not able to clinch a spot on our list of the 30 Most Popular Stocks Among Hedge Funds. BMY was in 66 hedge fund portfolios at the end of the fourth quarter of 2021, compared to 74 funds in the previous quarter. Bristol-Myers Squibb Company (NYSE:BMY) delivered an 18.28% return in the past 3 months.
In March 2022, we published an article that includes BMY in the 5 Safe Dividend Stocks to Buy Today. You can find other letters from hedge funds and prominent investors on our hedge fund investor letters 2021 Q4 page.
Disclosure: None. This article is originally published at Insider Monkey.
